Q2 Earnings Forecast for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Equities researchers at HC Wainwright increased their Q2 2025 earnings estimates for Annovis Bio in a research report issued to clients and investors on Monday, June 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.36) for the quarter, up from their previous estimate of ($0.49). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Annovis Bio's current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio's Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.45) EPS and FY2025 earnings at ($1.52) EPS.

Annovis Bio (NYSE:ANVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.15.

Separately, Canaccord Genuity Group lowered their target price on shares of Annovis Bio from $26.00 to $17.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Annovis Bio presently has an average rating of "Buy" and an average price target of $30.25.

Annovis Bio Price Performance

Annovis Bio stock traded down $0.13 during midday trading on Wednesday, reaching $2.82. The stock had a trading volume of 371,950 shares, compared to its average volume of 743,010. Annovis Bio has a twelve month low of $1.11 and a twelve month high of $17.88. The firm has a market cap of $54.85 million, a price-to-earnings ratio of -0.63 and a beta of 1.62. The firm's fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $3.03.

Institutional Trading of Annovis Bio

A number of large investors have recently added to or reduced their stakes in ANVS. Warberg Asset Management LLC bought a new stake in Annovis Bio in the 1st quarter valued at about $58,000. Lokken Investment Group LLC boosted its stake in shares of Annovis Bio by 60.3% in the 1st quarter. Lokken Investment Group LLC now owns 29,235 shares of the company's stock valued at $44,000 after purchasing an additional 11,000 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Annovis Bio during the 4th quarter worth approximately $55,000. Cubist Systematic Strategies LLC acquired a new stake in Annovis Bio during the 4th quarter worth approximately $258,000. Finally, Jane Street Group LLC boosted its position in Annovis Bio by 99.7% during the 4th quarter. Jane Street Group LLC now owns 68,107 shares of the company's stock worth $343,000 after buying an additional 34,001 shares during the period. Institutional investors and hedge funds own 15.83% of the company's stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.